|
1
|
Grady WM, Yu M and Markowitz SD:
Epigenetic alterations in the gastrointestinal tract: Current and
emerging use for biomarkers of cancer. Gastroenterology.
160:690–709. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Joshi SS and Badgwell BD: Current
treatment and recent progress in gastric cancer. CA Cancer J Clin.
71:264–279. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park W, Chawla A and O'Reilly EM:
Pancreatic cancer: A review. JAMA. 326:851–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
US Preventive Services Task Force, . Owens
DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry
SJ, Doubeni CA, Epling JW Jr, et al: Screening for pancreatic
cancer: US Preventive Services Task Force Reaffirmation
Recommendation statement. JAMA. 322:438–444. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sirica AE, Strazzabosco M and Cadamuro M:
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor
reactive microenvironment, and malignant progression. Adv Cancer
Res. 149:321–387. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song X, Hu Y, Li Y, Shao R, Liu F and Liu
Y: Overview of current targeted therapy in gallbladder cancer.
Signal Transduct Target Ther. 5:2302020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reichenbach ZW, Murray MG, Saxena R,
Farkas D, Karassik EG, Klochkova A, Patel K, Tice C, Hall TM, Gang
J, et al: Clinical and translational advances in esophageal
squamous cell carcinoma. Adv Cancer Res. 144:95–135. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Popovic D, Vucic D and Dikic I:
Ubiquitination in disease pathogenesis and treatment. Nat Med.
20:1242–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cockram PE, Kist M, Prakash S, Chen SH,
Wertz IE and Vucic D: Ubiquitination in the regulation of
inflammatory cell death and cancer. Cell Death Differ. 28:591–605.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikeda F: Ubiquitin conjugating enzymes in
the regulation of the autophagy-dependent degradation pathway.
Matrix Biol. 100–101. 23–29. 2021.PubMed/NCBI
|
|
13
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu W, Tang X, Qi X, Fu X, Ghimire S, Ma
R, Li S, Zhang N and Si H: The ubiquitin conjugating enzyme: An
important ubiquitin transfer platform in ubiquitin-proteasome
system. Int J Mol Sci. 21:28942020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye Y and Rape M: Building ubiquitin
chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 10:755–764.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hofmann RM and Pickart CM: In vitro
assembly and recognition of Lys-63 polyubiquitin chains. J Biol
Chem. 276:27936–27943. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park J, Cho J and Song EJ:
Ubiquitin-proteasome system (UPS) as a target for anticancer
treatment. Arch Pharm Res. 43:1144–1161. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bui QT, Hong JH, Kwak M, Lee JY and Lee
PC: Ubiquitin-Conjugating Enzymes in Cancer. Cells. 10:13832021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du X, Song H, Shen N, Hua R and Yang G:
The molecular basis of ubiquitin-conjugating enzymes (E2s) as a
potential target for cancer therapy. Int J Mol Sci. 22:34402021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Wijk SJ and Timmers HT: The family of
ubiquitin-conjugating enzymes (E2s): Deciding between life and
death of proteins. FASEB J. 24:981–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wiener R, DiBello AT, Lombardi PM, Guzzo
CM, Zhang X, Matunis MJ and Wolberger C: E2 ubiquitin-conjugating
enzymes regulate the deubiquitinating activity of OTUB1. Nat Struct
Mol Biol. 20:1033–1039. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stewart MD, Ritterhoff T, Klevit RE and
Brzovic PS: E2 enzymes: More than just middle men. Cell Res.
26:423–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hosseini SM, Okoye I, Chaleshtari MG,
Hazhirkarzar B, Mohamadnejad J, Azizi G, Hojjat-Farsangi M,
Mohammadi H, Shotorbani SS and Jadidi-Niaragh F: E2
ubiquitin-conjugating enzymes in cancer: Implications for
immunotherapeutic interventions. Clin Chim Acta. 498:126–134. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gehrke SG, Riedel HD, Herrmann T,
Hadaschik B, Bents K, Veltkamp C and Stremmel W: UbcH5A, a member
of human E2 ubiquitin-conjugating enzymes, is closely related to
SFT, a stimulator of iron transport, and is up-regulated in
hereditary hemochromatosis. Blood. 101:3288–3293. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Wang L, Xu X, Sun H and Wu L: LncRNA
HLA Complex Group 11 knockdown alleviates cisplatin resistance in
gastric cancer by targeting the miR-144-3p/UBE2D1 Axis. Cancer
Manag Res. 13:7543–7557. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie H, He Y, Wu Y and Lu Q: Silencing of
UBE2D1 inhibited cell migration in gastric cancer, decreasing
ubiquitination of SMAD4. Infect Agent Cancer. 16:632021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bergink S and Jentsch S: Principles of
ubiquitin and SUMO modifications in DNA repair. Nature.
458:461–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu
ZX, Ji HZ, Shao JG and Bian ZL: High expression of
ubiquitin-conjugating enzyme E2A predicts poor prognosis in
hepatocellular carcinoma. Oncol Lett. 15:7362–7368. 2018.PubMed/NCBI
|
|
29
|
Tokumoto M, Fujiwara Y, Shimada A,
Hasegawa T, Seko Y, Nagase H and Satoh M: Cadmium toxicity is
caused by accumulation of p53 through the down-regulation of Ube2d
family genes in vitro and in vivo. J Toxicol Sci. 36:191–200. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saville MK, Sparks A, Xirodimas DP,
Wardrop J, Stevenson LF, Bourdon JC, Woods YL and Lane DP:
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in
vivo. J Biol Chem. 279:42169–42181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou C, Bi F, Yuan J, Yang F and Sun S:
Gain of UBE2D1 facilitates hepatocellular carcinoma progression and
is associated with DNA damage caused by continuous IL-6. J Exp Clin
Cancer Res. 37:2902018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang A, Ding X, Demarque M, Liu X, Pan D,
Xin H, Zhong B, Wang X, Dejean A, Jin W and Dong C: Ubc9 is
required for positive selection and late-stage maturation of
thymocytes. J Immunol. 198:3461–3470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gupta MK, McLendon PM, Gulick J, James J,
Khalili K and Robbins J: UBC9-mediated sumoylation favorably
impacts cardiac function in compromised hearts. Circ Res.
118:1894–1905. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan
J, Qiang B and Peng X: microRNA-214-mediated UBC9 expression in
glioma. BMB Rep. 45:641–646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY:
Ubc9 promotes breast cell invasion and metastasis in a
sumoylation-independent manner. Oncogene. 29:1763–1772. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fang S, Qiu J, Wu Z, Bai T and Guo W:
Down-regulation of UBC9 increases the sensitivity of hepatocellular
carcinoma to doxorubicin. Oncotarget. 8:49783–49795. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsai CL, Liu WL, Hsu FM, Yang PS, Yen RF,
Tzen KY, Cheng AL, Chen PJ and Cheng JC: Targeting histone
deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for
radiosensitization of hepatocellular carcinoma cells in mice.
Hepatology. 67:586–599. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang H, Gao S, Chen J and Lou W: UBE2I
promotes metastasis and correlates with poor prognosis in
hepatocellular carcinoma. Cancer Cell Int. 20:2342020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang XK, Liao XW, Zhou X, Han CY, Chen ZJ,
Yang CK, Huang JL, Wang JY, Liu JQ, Huang HS, et al: Oncogene UBE2I
enhances cellular invasion, migration and proliferation abilities
via autophagy-related pathway resulting in poor prognosis in
hepatocellular carcinoma. Am J Cancer Res. 10:4178–4197.
2020.PubMed/NCBI
|
|
40
|
Reyes-Hernandez OD, Mejia-Garcia A,
Sanchez-Ocampo EM, Cabañas-Cortés MA, Ramírez P, Chávez-González L,
Gonzalez FJ and Elizondo G: Ube2l3 gene expression is modulated by
activation of the aryl hydrocarbon receptor: Implications for p53
ubiquitination. Biochem Pharmacol. 80:932–940. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Whitcomb EA, Dudek EJ, Liu Q and Taylor A:
Novel control of S phase of the cell cycle by ubiquitin-conjugating
enzyme H7. Mol Biol Cell. 20:1–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tao NN, Zhang ZZ, Ren JH, Zhang J, Zhou
YJ, Wai Wong VK, Kwan Law BY, Cheng ST, Zhou HZ, Chen WX, et al:
Overexpression of ubiquitin-conjugating enzyme E2 L3 in
hepatocellular carcinoma potentiates apoptosis evasion by
inhibiting the GSK3β/p65 pathway. Cancer Lett. 481:1–14. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dikshit A, Jin YJ, Degan S, Hwang J,
Foster MW, Li CY and Zhang JY: UBE2N promotes melanoma growth via
MEK/FRA1/SOX10 signaling. Cancer Res. 78:6462–6472. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang E, Liu Q, Wang Y, Wang H, He L, Jin
X and Li N: MicroRNA miR-147b promotes tumor growth via targeting
UBE2N in hepatocellular carcinoma. Oncotarget. 8:114072–114080.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shang M, Weng L, Xu G, Wu S, Liu B, Yin X,
Mao A, Zou X and Wang Z: TRIM11 suppresses ferritinophagy and
gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in
pancreatic ductal adenocarcinoma. J Cell Physiol. 236:6868–6883.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shekhar MP, Gerard B, Pauley RJ, Williams
BO and Tait L: Rad6B is a positive regulator of beta-catenin
stabilization. Cancer Res. 68:1741–1750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang WL, Luo CW, Chou CL, Yang CC, Chen
TJ, Li CF and Pan MR: High expression of UBE2B as a Poor prognosis
factor in patients with rectal cancer following chemoradiotherapy.
Anticancer Res. 40:6305–6317. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M,
Miyazaki M and Nakagawara A: UbcH10 Is the Cancer-related E2
Ubiquitin-conjugating Enzyme. Cancer Res. 63:4167–4173.
2003.PubMed/NCBI
|
|
49
|
Zhang H, Zhao G, Ke B, Ma G, Liu GL, Liang
H, Liu LR and Hao XS: Overexpression of UBE2C correlates with poor
prognosis in gastric cancer patients. Eur Rev Med Pharmacol Sci.
22:1665–1671. 2018.PubMed/NCBI
|
|
50
|
Wang Y, Huang F, Liu M and Zhao Q: UBE2C
mRNA expression controlled by miR-300 and HuR determines its
oncogenic role in gastric cancer. Biochem Biophys Res Commun.
534:597–603. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Y, Han T, Wei G and Wang Y:
Inhibition of microRNA-17/20a suppresses cell proliferation in
gastric cancer by modulating UBE2C expression. Oncol Rep.
33:2529–2536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang R, Song Y, Liu X, Wang Q, Wang Y, Li
L, Kang C and Zhang Q: UBE2C induces EMT through Wnt/β-catenin and
PI3K/Akt signaling pathways by regulating phosphorylation levels of
Aurora-A. Int J Oncol. 50:1116–1126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang M, Qu Y, Shi R, Wu X, Su C, Hu Z,
Chang Q, Liu S, Pan G, Lei M, et al: Ubiquitin-conjugating enzyme
UbcH10 promotes gastric cancer growth and is a potential biomarker
for gastric cancer. Oncol Rep. 36:779–786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ieta K, Ojima E, Tanaka F, Nakamura Y,
Haraguchi N, Mimori K, Inoue H, Kuwano H and Mori M: Identification
of overexpressed genes in hepatocellular carcinoma, with special
reference to ubiquitin-conjugating enzyme E2C gene expression. Int
J Cancer. 121:33–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhu M, Wu M, Bian S, Song Q, Xiao M, Huang
H, You L, Zhang J, Zhang J, Cheng C, et al: DNA primase subunit 1
deteriorated progression of hepatocellular carcinoma by activating
AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. Cell
Biosci. 11:422021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wei Z, Liu Y, Qiao S, Li X, Li Q, Zhao J,
Hu J, Wei Z, Shan A, Sun X and Xu B: Identification of the
potential therapeutic target gene UBE2C in human hepatocellular
carcinoma: An investigation based on GEO and TCGA databases. Oncol
Lett. 17:5409–5418. 2019.PubMed/NCBI
|
|
57
|
Xiong Y, Lu J, Fang Q, Lu Y, Xie C, Wu H
and Yin Z: UBE2C functions as a potential oncogene by enhancing
cell proliferation, migration, invasion, and drug resistance in
hepatocellular carcinoma cells. Biosci Rep. 39:BSR201823842019.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhou W, Xu J, Tan M, Li H, Li H, Wei W and
Sun Y: UBE2M is a stress-inducible dual E2 for neddylation and
ubiquitylation that promotes targeted degradation of UBE2F. Mol
Cell. 70:1008–1024. e62018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang GC, Yu XN, Sun JL, Xiong J, Yang YJ,
Jiang XM and Zhu JM: UBE2M promotes cell proliferation via the
β-catenin/cyclin D1 signaling in hepatocellular carcinoma. Aging
(Albany NY). 12:2373–2392. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang B, Deng C, Wang L, Zhou F, Zhang S,
Kang W, Zhan P, Chen J, Shen S, Guo H, et al: Upregulation of
UBE2Q1 via gene copy number gain in hepatocellular carcinoma
promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR
signaling pathway. Mol Carcinog. 57:201–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chang R, Wei L, Lu Y, Cui X, Lu C, Liu L,
Jiang D, Xiong Y, Wang G, Wan C and Qian H: Upregulated expression
of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with
enhanced cell proliferation and poor prognosis in human
hapatocellular carcinoma. J Mol Histol. 46:45–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hu N, Fan XP, Fan YC, Chen LY, Qiao CY,
Han LY and Wang K: Hypomethylated ubiquitin-conjugating enzyme2 Q1
(UBE2Q1) gene promoter in the serum is a promising biomarker for
hepatitis B Virus-associated hepatocellular carcinoma. Tohoku J Exp
Med. 242:93–100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang X, Yin L, Yang L, Zheng Y, Liu S,
Yang J, Cui H and Wang H: Silencing ubiquitin-conjugating enzyme 2C
inhibits proliferation and epithelial-mesenchymal transition in
pancreatic ductal adenocarcinoma. FEBS J. 286:4889–4909. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q,
Yin W, Cheng XD, Zhang W and Qin JJ: Targeting E2
ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor
suppresses pancreatic cancer growth and metastasis. Mol Cancer.
21:702022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen S, Chen Y, Hu C, Jing H, Cao Y and
Liu X: Association of clinicopathological features with UbcH10
expression in colorectal cancer. J Cancer Res Clin Oncol.
136:419–426. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fujita T, Ikeda H, Taira N, Hatoh S, Naito
M and Doihara H: Overexpression of UbcH10 alternates the cell cycle
profile and accelerate the tumor proliferation in colon cancer. BMC
Cancer. 9:872009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cacciola NA, Calabrese C, Malapelle U,
Pellino G, De Stefano A, Sepe R, Sgariglia R, Quintavalle C,
Federico A, Bianco A, et al: UbcH10 expression can predict
prognosis and sensitivity to the antineoplastic treatment for
colorectal cancer patients. Mol Carcinog. 55:793–807. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li SZ, Song Y, Zhang HH, Jin BX, Liu Y,
Liu WB, Zhang XD and Du RL: UbcH10 overexpression increases
carcinogenesis and blocks ALLN susceptibility in colorectal cancer.
Sci Rep. 4:69102014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen SM, Jiang CY, Wu JY, Liu B, Chen YJ,
Hu CJ and Liu XX: RNA interference-mediated silencing of UBCH10
gene inhibits colorectal cancer cell growth in vitro and in vivo.
Clin Exp Pharmacol Physiol. 37:525–529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang Y, Tian S, Li X, Ji Y, Wang Z and
Liu C: UBE2C promotes rectal carcinoma via miR-381. Cancer Biol
Ther. 19:230–238. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R,
Abubaker J, Sultana M, Al-Sanea N, Abduljabbar A, Ashari LH, et al:
Bortezomib stabilizes mitotic cyclins and prevents cell cycle
progression via inhibition of UBE2C in colorectal carcinoma. Am J
Pathol. 178:2109–2120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shafiee SM, Seghatoleslam A, Nikseresht M,
Hosseini SV, Alizadeh-Naeeni M, Safaei A and Owji AA: UBE2Q1
expression in human colorectal tumors and cell lines. Mol Biol Rep.
40:7045–7051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Fahmidehkar MA, Shafiee SM, Eftekhar E,
Mahbudi L and Seghatoleslam A: Induction of cell proliferation,
clonogenicity and cell accumulation in S phase as a consequence of
human UBE2Q1 overexpression. Oncol Lett. 12:2169–2174. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Shafiee S, Seghatoleslam A, Nikseresht M,
Hosseini SV, Alizadeh-Naeeni M, Safaei A and Owji AA: Expression
status of UBE2Q2 in colorectal primary tumors and cell lines. Iran
J Med Sci. 39 (Suppl 2):S196–S202. 2014.PubMed/NCBI
|
|
75
|
Mokarram P, Shakiba-Jam F, Kavousipour S,
Sarabi MM and Seghatoleslam A: Promoter methylation status of two
novel human genes, UBE2Q1 and UBE2Q2, in colorectal cancer: A new
finding in Iranian patients. Asian Pac J Cancer Prev. 16:8247–8252.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shen T, Cai LD, Liu YH, Li S, Gan WJ, Li
XM, Wang JR, Guo PD, Zhou Q, Lu XX, et al: Ube2v1-mediated
ubiquitination and degradation of Sirt1 promotes metastasis of
colorectal cancer by epigenetically suppressing autophagy. J
Hematol Oncol. 11:952018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Washiro M, Ohtsuka M, Kimura F, Shimizu H,
Yoshidome H, Sugimoto T, Seki N and Miyazaki M: Upregulation of
topoisomerase IIalpha expression in advanced gallbladder carcinoma:
A potential chemotherapeutic target. J Cancer Res Clin Oncol.
134:793–801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhao B, Gao C, Shi D, Mao J, Zhao J, Guo
L, Guo J and Jiao Z: Knockdown of Nedd8conjugating enzyme UBE2M
suppresses the proliferation and induces the apoptosis of
intrahepatic cholangiocarcinoma cells. Oncol Rep. 42:2670–2679.
2019.PubMed/NCBI
|
|
79
|
Wang X, Li G, Luo Q and Gan C:
Identification of crucial genes associated with esophageal squamous
cell carcinoma by gene expression profile analysis. Oncol Lett.
15:8983–8990. 2018.PubMed/NCBI
|
|
80
|
Dastsooz H, Cereda M, Donna D and Oliviero
S: A comprehensive bioinformatics analysis of UBE2C in cancers. Int
J Mol Sci. 20:22282019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li J, Xie Y, Wang X, Jiang C, Yuan X,
Zhang A, Yang L, Liu C, Zou H, Li F and Hu J: Identification of hub
genes associated with esophageal cancer progression using
bioinformatics analysis. Oncol Lett. 20:2142020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Matsumoto A, Ishibashi Y, Urashima M,
Omura N, Nakada K, Nishikawa K, Shida A, Takada K, Kashiwagi H and
Yanaga K: High UBCH10 protein expression as a marker of poor
prognosis in esophageal squamous cell carcinoma. Anticancer Res.
34:955–961. 2014.PubMed/NCBI
|
|
83
|
Li R, Pang XF, Huang ZG, Yang LH, Peng ZG,
Ma J and He RQ: Overexpression of UBE2C in esophageal squamous cell
carcinoma tissues and molecular analysis. BMC Cancer. 21:9962021.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li L, Li X, Wang W, Gao T and Shi Z: UBE2C
is involved in the functions of ECRG4 on esophageal squamous cell
carcinoma. Biomed Pharmacother. 98:201–206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wu J, Tian B, Yang J, Huo H, Song Z, Yu J
and Gu Y: Reduction of Hip2 suppresses gastric cancer cell
proliferation, migration, invasion and tumorigenesis. Transl Cancer
Res. 9:774–785. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Machida YJ, Machida Y, Chen Y, Gurtan AM,
Kupfer GM, D'Andrea AD and Dutta A: UBE2T is the E2 in the Fanconi
anemia pathway and undergoes negative autoregulation. Mol Cell.
23:589–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yu H, Xiang P, Pan Q, Huang Y, Xie N and
Zhu W: Ubiquitin-Conjugating Enzyme E2T is an independent
prognostic factor and promotes gastric cancer progression. Tumour
Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang
J, Cao H, Zhang G, Li Y and Jiao Z: UBE2T knockdown inhibits
gastric cancer progression. Oncotarget. 8:32639–32654. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren
W, Li H, Zhao L, Liu H, Yan H, et al: A novel UBE2T inhibitor
suppresses Wnt/β-catenin signaling hyperactivation and gastric
cancer progression by blocking RACK1 ubiquitination. Oncogene.
40:1027–1042. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Garnett MJ, Mansfeld J, Godwin C,
Matsusaka T, Wu J, Russell P, Pines J and Venkitaraman AR: UBE2S
elongates ubiquitin chains on APC/C substrates to promote mitotic
exit. Nat Cell Biol. 11:1363–1369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhang CY and Yang M: Functions of three
ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma
diagnosis and prognosis. World J Hepatol. 14:956–971. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Pan YH, Yang M, Liu LP, Wu DC, Li MY and
Su SG: UBE2S enhances the ubiquitination of p53 and exerts
oncogenic activities in hepatocellular carcinoma. Biochem Biophys
Res Commun. 503:895–902. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ma Y, Li K, Li S, Liang B, Liu Q and Mo Z:
Prognostic value of ubiquitin-conjugating enzyme E2 S
overexpression in hepatocellular carcinoma. Int J Biol Macromol.
119:225–231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Gui L, Zhang S, Xu Y, Zhang H, Zhu Y and
Kong L: UBE2S promotes cell chemoresistance through PTEN-AKT
signaling in hepatocellular carcinoma. Cell Death Discov.
7:3572021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhao X, Weng W, Jin M, Li S, Chen Q, Li B,
Zhou Z, Lan C and Yang Y: Identification of biomarkers based on
bioinformatics analysis: The expression of ubiquitin-conjugating
enzyme E2T (UBE2T) in the carcinogenesis and progression of
hepatocellular carcinoma. Med Sci Monit. 27:e9290232021.PubMed/NCBI
|
|
96
|
Ren X, Li A, Ying E, Fang J, Li M and Yu
J: Upregulation of ubiquitin-conjugating enzyme E2T (UBE2T)
predicts poor prognosis and promotes hepatocellular carcinoma
progression. Bioengineered. 12:1530–1542. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wei X, You X, Zhang J and Zhou C:
MicroRNA-1305 inhibits the stemness of LCSCs and tumorigenesis by
repressing the UBE2T-Dependent akt-signaling pathway. Mol Ther
Nucleic Acids. 16:721–732. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Liu LL, Zhu JM, Yu XN, Zhu HR, Shi X,
Bilegsaikhan E, Guo HY, Wu J and Shen XZ: UBE2T promotes
proliferation via G2/M checkpoint in hepatocellular carcinoma.
Cancer Manag Res. 11:8359–8370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Guo J, Wang M, Wang J and Wu C:
Ubiquitin-conjugating enzyme E2T knockdown suppresses
hepatocellular tumorigenesis via inducing cell cycle arrest and
apoptosis. World J Gastroenterol. 25:6386–6403. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liu LP, Yang M, Peng QZ, Li MY, Zhang YS,
Guo YH, Chen Y and Bao SY: UBE2T promotes hepatocellular carcinoma
cell growth via ubiquitination of p53. Biochem Biophys Res Commun.
493:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Tao Y, Li R, Shen C, Li J, Zhang Q, Ma Z,
Wang F and Wang Z: SENP1 is a crucial promotor for hepatocellular
carcinoma through deSUMOylation of UBE2T. Aging (Albany NY).
12:1563–1576. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q,
Guo Z, Liu L and Wu D: UBE2T-regulated H2AX monoubiquitination
induces hepatocellular carcinoma radioresistance by facilitating
CHK1 activation. J Exp Clin Cancer Res. 39:2222020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zheng YW, Gao PF, Ma MZ, Chen Y and Li CY:
Role of ubiquitin-conjugating enzyme E2T in the carcinogenesis and
progression of pancreatic cancer. Oncol Lett. 20:1462–1468. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang L, Liang Y, Li P, Liang Q, Sun H, Xu
D and Hu W: Oncogenic Activities Of UBE2S Mediated By VHL/HIF-1α
/STAT3 Signal Via the ubiquitin-proteasome system In PDAC. Onco
Targets Ther. 12:9767–9781. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li Z, Wang Y, Li Y, Yin W, Mo L, Qian X,
Zhang Y, Wang G, Bu F, Zhang Z, et al: Ube2s stabilizes
beta-Catenin through K11-linked polyubiquitination to promote
mesendoderm specification and colorectal cancer development. Cell
Death Dis. 9:4562018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Luo M and Zhou Y: Comprehensive analysis
of differentially expressed genes reveals the promotive effects of
UBE2T on colorectal cancer cell proliferation. Oncol Lett.
22:7142021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wu X, Liu G, Liu R, He J, Wang G, Zhang H,
Liu T, Bai J, Cheng N and Qiu J: Expression of
ubiquitin-conjugating enzyme E2T in colorectal cancers and clinical
implications. Oncol Lett. 20:2752020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wu M, Li X, Huang W, Chen Y, Wang B and
Liu X: Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal
cancer progression by facilitating ubiquitination and degradation
of p53. Clin Res Hepatol Gastroenterol. 45:1014932021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhu X, Li T, Niu X, Chen L and Ge C:
Identification of UBE2T as an independent prognostic biomarker for
gallbladder cancer. Oncol Lett. 20:442020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yu H, Wang H, Dong W, Cao ZY, Li R, Yang
C, Cong WM, Dong H and Jin GZ: The diagnostic and prognostic value
of UBE2T in intrahepatic cholangiocarcinoma. PeerJ. 8:e84542020.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu F, Zhu C, Gao P, Zheng S and Li C:
Ubiquitin-conjugating enzyme E2T regulates cell proliferation and
migration in cholangiocarcinoma. Anticancer Drugs. 31:836–846.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wang X, Liu Y, Leng X, Cao K, Sun W, Zhu J
and Ma J: UBE2T contributes to the prognosis of esophageal squamous
cell carcinoma. Pathol Oncol Res. 27:6325312021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Shi Z, Liu R, Lu Q, Zeng Z, Liu Y, Zhao J,
Liu X, Li L, Huang H, Yao Y, et al: UBE2O promotes hepatocellular
carcinoma cell proliferation and invasion by regulating the
AMPKalpha2/mTOR pathway. Int J Med Sci. 18:3749–3758. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Shi X, Wang B, Chen X, Zheng Y, Ding Y and
Wang C: Upregulation of ubiquitin-conjugating enzyme E2Z is
associated with human hepatocellular carcinoma. Biochem Biophys Res
Commun. 523:25–32. 2020. View Article : Google Scholar : PubMed/NCBI
|
